HC Wainwright Issues Positive Forecast for Genelux Earnings

Genelux Co. (NASDAQ:GNLX - Free Report) - Equities research analysts at HC Wainwright boosted their Q2 2025 EPS estimates for Genelux in a note issued to investors on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.22) per share for the quarter, up from their prior estimate of ($0.24). HC Wainwright has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Genelux's current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux's Q3 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.96) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at $0.44 EPS and FY2029 earnings at $1.44 EPS.

Genelux (NASDAQ:GNLX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.03.

Separately, Benchmark cut their price target on shares of Genelux from $25.00 to $23.00 and set a "speculative buy" rating on the stock in a report on Thursday, May 8th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $17.75.

Genelux Trading Down 3.2%

Shares of Genelux stock traded down $0.08 during trading hours on Friday, reaching $2.40. The stock had a trading volume of 145,589 shares, compared to its average volume of 213,704. Genelux has a 1 year low of $1.60 and a 1 year high of $5.89. The firm has a market capitalization of $90.56 million, a price-to-earnings ratio of -2.53 and a beta of -0.33. The firm has a 50 day simple moving average of $2.92 and a two-hundred day simple moving average of $3.11.

Hedge Funds Weigh In On Genelux

Several institutional investors and hedge funds have recently made changes to their positions in GNLX. Virtu Financial LLC bought a new position in Genelux during the 4th quarter valued at $25,000. Advisor Resource Council bought a new position in shares of Genelux during the first quarter worth about $34,000. Apollon Wealth Management LLC grew its stake in Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company's stock worth $40,000 after purchasing an additional 2,857 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Genelux in the fourth quarter valued at about $41,000. Finally, Liberty Wealth Management LLC acquired a new stake in Genelux during the first quarter valued at approximately $45,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.